T0	KEYPHRASE-NOTYPES 27 35	patients
T1	KEYPHRASE-NOTYPES 41 43	EM
T2	KEYPHRASE-NOTYPES 52 76	brief recurrent episodes
T3	KEYPHRASE-NOTYPES 80 89	arthritis
T4	KEYPHRASE-NOTYPES 125 136	arthralgias
T5	KEYPHRASE-NOTYPES 141 149	myalgias
T6	KEYPHRASE-NOTYPES 152 153	]
T7	KEYPHRASE-NOTYPES 155 163	Patients
T8	KEYPHRASE-NOTYPES 169 171	EM
T9	KEYPHRASE-NOTYPES 194 211	antibiotics today
T10	KEYPHRASE-NOTYPES 245 254	arthritis
T11	KEYPHRASE-NOTYPES 267 275	patients
T12	KEYPHRASE-NOTYPES 291 299	LA today
T13	KEYPHRASE-NOTYPES 328 335	subsets
T14	KEYPHRASE-NOTYPES 339 347	patients
T15	KEYPHRASE-NOTYPES 354 356	EM
T16	KEYPHRASE-NOTYPES 409 411	EM
T17	KEYPHRASE-NOTYPES 419 453	typical early manifestations
T18	KEYPHRASE-NOTYPES 457 469	Lyme disease
T19	KEYPHRASE-NOTYPES 499 505	adults
T20	KEYPHRASE-NOTYPES 532 540	children
T21	KEYPHRASE-NOTYPES 546 548	LA
T22	KEYPHRASE-NOTYPES 558 569	tick bite [
T23	KEYPHRASE-NOTYPES 573 581	247-250 ]
T24	KEYPHRASE-NOTYPES 615 621	adults
T25	KEYPHRASE-NOTYPES 629 636	history
T26	KEYPHRASE-NOTYPES 640 644	EM [
T27	KEYPHRASE-NOTYPES 647 648	]
T28	KEYPHRASE-NOTYPES 658 669	case series
T29	KEYPHRASE-NOTYPES 691 702	last decade
T30	KEYPHRASE-NOTYPES 707 708	]
T31	KEYPHRASE-NOTYPES 720 730	proportion
T32	KEYPHRASE-NOTYPES 734 742	children
T33	KEYPHRASE-NOTYPES 775 789	recent cohorts
T34	KEYPHRASE-NOTYPES 802 803	]
T35	KEYPHRASE-NOTYPES 818 822	data
T36	KEYPHRASE-NOTYPES 830 849	large vaccine trial
T37	KEYPHRASE-NOTYPES 859 871	participants
T38	KEYPHRASE-NOTYPES 908 916	patients
T39	KEYPHRASE-NOTYPES 922 934	Bb infection
T40	KEYPHRASE-NOTYPES 945 962	systemic symptoms
T41	KEYPHRASE-NOTYPES 974 983	headaches
T42	KEYPHRASE-NOTYPES 988 999	arthralgias
T43	KEYPHRASE-NOTYPES 1005 1006	]
T44	KEYPHRASE-NOTYPES 1046 1058	Lyme disease
T45	KEYPHRASE-NOTYPES 1066 1073	patient
T46	KEYPHRASE-NOTYPES 1081 1099	treating physician
T47	KEYPHRASE-NOTYPES 1128 1140	participants
T48	KEYPHRASE-NOTYPES 1146 1173	asymptomatic seroconversion
T49	KEYPHRASE-NOTYPES 1181 1182	]
T50	KEYPHRASE-NOTYPES 1199 1218	worst-case scenario
T51	KEYPHRASE-NOTYPES 1241 1258	patient subgroups
T52	KEYPHRASE-NOTYPES 1267 1269	LA
T53	KEYPHRASE-NOTYPES 1288 1297	arthritis
T54	KEYPHRASE-NOTYPES 1319 1332	manifestation
T55	KEYPHRASE-NOTYPES 1349 1357	patients
T56	KEYPHRASE-NOTYPES 1363 1375	Lyme disease
T57	KEYPHRASE-NOTYPES 1383 1385	US
T58	KEYPHRASE-NOTYPES 1387 1393	Rather
T59	KEYPHRASE-NOTYPES 1408 1416	patients
T60	KEYPHRASE-NOTYPES 1422 1424	LA
T61	KEYPHRASE-NOTYPES 1459 1464	cases
T62	KEYPHRASE-NOTYPES 1481 1486	CDC [
T63	KEYPHRASE-NOTYPES 1489 1490	]
T64	KEYPHRASE-NOTYPES 1495 1503	contrast
T65	KEYPHRASE-NOTYPES 1509 1522	observed rate
T66	KEYPHRASE-NOTYPES 1526 1543	large case series
T67	KEYPHRASE-NOTYPES 1547 1553	adults
T68	KEYPHRASE-NOTYPES 1558 1566	children
T69	KEYPHRASE-NOTYPES 1572 1584	Lyme disease
T70	KEYPHRASE-NOTYPES 1605 1606	]
T71	KEYPHRASE-NOTYPES 1612 1623	words
T72	KEYPHRASE-NOTYPES 1629 1637	majority
T73	KEYPHRASE-NOTYPES 1641 1646	cases
T74	KEYPHRASE-NOTYPES 1650 1652	LA
T75	KEYPHRASE-NOTYPES 1660 1662	US
T76	KEYPHRASE-NOTYPES 1693 1695	LA
T77	KEYPHRASE-NOTYPES 1716 1721	cases
T78	KEYPHRASE-NOTYPES 1725 1741	Lyme borreliosis
T79	KEYPHRASE-NOTYPES 1745 1777	European epidemiological studies
T80	KEYPHRASE-NOTYPES 1791 1792	]
T81	KEYPHRASE-NOTYPES 1807 1814	results
T82	KEYPHRASE-NOTYPES 1820 1833	Swedish study
T83	KEYPHRASE-NOTYPES 1847 1849	LA
T84	KEYPHRASE-NOTYPES 1876 1877	]
T85	KEYPHRASE-NOTYPES 1885 1897	Lyme disease
T86	KEYPHRASE-NOTYPES 1914 1917	men
T87	KEYPHRASE-NOTYPES 1922 1927	women
T88	KEYPHRASE-NOTYPES 1933 1950	similar frequency
T89	KEYPHRASE-NOTYPES 1965 1971	adults
T90	KEYPHRASE-NOTYPES 1983 1991	children
T91	KEYPHRASE-NOTYPES 1997 1999	LA
T92	KEYPHRASE-NOTYPES 2025 2029	US [
T93	KEYPHRASE-NOTYPES 2047 2055	256-258 ]
T94	KEYPHRASE-NOTYPES 2069 2077	Europe [
T95	KEYPHRASE-NOTYPES 2096 2097	]
